UnitedHealth Group is viewed as a turnaround opportunity with management focusing on margin expansion rather than revenue growth for 2026-2027. Recent CMS rate hikes and restructuring in Optum Health support a positive outlook, suggesting potential revenue and profit gains not yet reflected in the stock price. Trading near the low end of its historical price-to-earnings range, UNH could see over 30% upside if margins improve and valuation multiples normalize. The analyst maintains a 'Buy' rating ahead of Q1 earnings, expecting margin stability, positive guidance, and benefits from AI-driven cost-saving initiatives.
Piper Sandler raised its price target for UnitedHealth Group to $475, suggesting a 13.3% upside from its current price of $419.23. The company, the largest U.S. health insurer, has consistently beaten earnings estimates, with its latest EPS of $7.23 ...
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
Elevance Health and UnitedHealth Group, two of the largest U.S. health insurers, are set to report their second-quarter earnings this week. Investors and analysts are watching closely to see if these companies have maintained control over rising medi...
